Shares of Synthetic Biologics, Inc (NASDAQ:SYN) have earned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports.
Zacks has also assigned Synthetic Biologics an industry rank of 78 out of 256 based on the ratings given to related companies.
Separately, William Blair reiterated an “outperform” rating on shares of Synthetic Biologics in a report on Thursday, February 28th.
Synthetic Biologics (NASDAQ:SYN) last issued its earnings results on Wednesday, February 27th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.95).
About Synthetic Biologics
Synthetic Biologics, Inc, a late-stage clinical company, develops therapeutics designed to preserve the microbiome to protect and restore the health of patients. Its lead product candidates are in Phase III development, such as SYN-004 that is designed to protect the gut microbiome from the effects of commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C.
See Also: Gross Domestic Product (GDP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with MarketBeat.com's FREE daily email newsletter.